Literature DB >> 22054883

The use and misuse of positron emission tomography in lung cancer evaluation.

Ching-Fei Chang1, Afshin Rashtian, Michael K Gould.   

Abstract

This article discusses the potential benefits and limitations of positron emission tomography (PET) for characterizing lung nodules, staging the mediastinum, identifying occult distant metastasis, determining prognosis and treatment response, guiding plans for radiation therapy, restaging during and after treatment, and selecting targets for tissue sampling. The key findings from the medical literature are presented regarding the capabilities and fallibilities of PET in lung cancer evaluation, including characterization of pulmonary nodules and staging in patients with known or suspected non-small-cell lung cancer. The discussion is limited to PET imaging with fluorodeoxyglucose. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22054883      PMCID： PMC3210441          DOI： 10.1016/j.ccm.2011.08.012

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN： 0272-5231            Impact factor:   2.878


  88 in total

Review 1.  Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer.

Authors:  Frank C Detterbeck; Steven Falen; M Patricia Rivera; Jan S Halle; Mark A Socinski
Journal:  Chest       Date:  2004-06       Impact factor: 9.410

Review 2.  Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses.

Authors:  Frank C Detterbeck; Steven Falen; M Patricia Rivera; Jan S Halle; Mark A Socinski
Journal:  Chest       Date:  2004-06       Impact factor: 9.410

3.  Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.

Authors:  W J Scott; J Shepherd; S S Gambhir
Journal:  Ann Thorac Surg       Date:  1998-12       Impact factor: 4.330

4.  The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules.

Authors:  S J Swensen; M D Silverstein; D M Ilstrup; C D Schleck; E S Edell
Journal:  Arch Intern Med       Date:  1997-04-28

5.  The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.

Authors:  Robert James Cerfolio; Buddhiwardhani Ojha; Ayesha S Bryant; Vanguru Raghuveer; James M Mountz; Alfred A Bartolucci
Journal:  Ann Thorac Surg       Date:  2004-09       Impact factor: 4.330

Review 6.  Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.

Authors:  Johan Vansteenkiste; Barbara M Fischer; Christophe Dooms; Jann Mortensen
Journal:  Lancet Oncol       Date:  2004-09       Impact factor: 41.316

7.  Analytical decision model for the cost-effective management of solitary pulmonary nodules.

Authors:  S S Gambhir; J E Shepherd; B D Shah; E Hart; C K Hoh; P E Valk; T Emi; M E Phelps
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

8.  Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer.

Authors:  Rosalie C Viney; Michael J Boyer; Madeleine T King; Patricia M Kenny; Christine A Pollicino; Jocelyn M McLean; Brian C McCaughan; Michael J Fulham
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.

Authors:  K M Pisters; M G Kris; R J Gralla; M B Zaman; R T Heelan; N Martini
Journal:  J Clin Oncol       Date:  1993-09       Impact factor: 44.544

10.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.

Authors:  S S Gambhir; C K Hoh; M E Phelps; I Madar; J Maddahi
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057
View more
  3 in total

1.  Intraoperative Molecular Imaging in Lung Cancer: The State of the Art and the Future.

Authors:  Stephan Rogalla; Sebastiaan C M Joosten; Israt S Alam; Sanjiv S Gambhir; Ophir Vermesh
Journal:  Mol Ther       Date:  2018-02-02       Impact factor: 11.454

2.  Use and Outcomes of SBRT for Early Stage NSCLC Without Pathologic Confirmation in the Veterans Health Care Administration.

Authors:  Joel R Wilkie; Rachel Lipson; Matthew C Johnson; Christina Williams; Drew Moghanaki; David Elliott; Dawn Owen; Namratha Atluri; Shruti Jolly; Christina Hunter Chapman
Journal:  Adv Radiat Oncol       Date:  2021-04-20

3.  Challenges and opportunities in patient-specific, motion-managed and PET/CT-guided radiation therapy of lung cancer: review and perspective.

Authors:  Stephen R Bowen; Matthew J Nyflot; Michael Gensheimer; Kristi R G Hendrickson; Paul E Kinahan; George A Sandison; Shilpen A Patel
Journal:  Clin Transl Med       Date:  2012-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.